An adaptive clinical trial of Evusheld and COVID-19 vaccination in immunosuppressed patients highly vulnerable to infection with COVID-19
Which hospital sites are involved in the study?
PLEASE NOTE: Cohorts 1a (Haematological malignancy receiving active therapy with immunosuppressive or immunomodulating agents) and 4b (Participants receiving non-rituximab immunosuppressants for inflammatory disorders) are currently both closed to recruitment at all sites other than Churchill Hospital Oxford.
Churchill Hospital, Oxford, Oxford University Hospitals (OUH) NHS Foundation Trust
University Hospital of Wales, Cardiff, Cardiff and Vale University Local Health Board
The Clatterbridge Cancer Centre, Liverpool, TheClatterbridge Cancer Centre NHS Foundation Trust
Northampton General Hospital, Northampton, Northampton General Hospital NHS Trust
The Royal Marsden Hospital, Sutton, The Royal Marsden NHS Foundation Trust - ONLY ACCEPTING CANCER PATIENTS
If eligible and you feel you could feasibly attend one of the hospital sites above for the follow-up appointments (there will be 7 follow-up visits in total that will take place across 1 year), you must be referred by your GP or hospital doctor to one of the participating hospitals. Your doctor will contact the doctor responsible for RAPID-PROTECTION at your hospital should you match the trial criteria.
THE DECISION TO ACCEPT THIS REFERRAL ULTIMATELY LIES WITH EACH PARTICIPATING HOSPITAL.
